Aquestive Therapeutics, Inc.
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $44.5M
- Net income
- -$83.8M
- Total assets
- $160.4M
- Market cap
- $493.0M
- Gross margin
- 58.3%
- Operating margin
- -159.5%
- Net margin
- -188.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $44.5M
- Cost of revenue
- $18.6M
- Gross profit
- $26.0M
- Operating expenses
- $97.0M
- Operating income
- -$71.1M
- Income tax
- $0
- Net income
- -$83.8M
- EPS (basic)
- $-0.78
- EPS (diluted)
- $-0.78
Balance sheet
- Total assets
- $160.4M
- Current assets
- $149.3M
- Total liabilities
- $194.1M
- Current liabilities
- $47.6M
- Shareholders’ equity
- -$33.7M
Cash flow
- Operating cash flow
- -$52.4M
- Investing cash flow
- -$562.0K
- Financing cash flow
- $102.6M
- Net cash flow
- $49.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $493.0M
- EPS (diluted)
- $-0.78
- Shares outstanding
- 126.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 25, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $83.8M in FY2025.
- Revenue declined 12% from FY2021 to FY2025.
- Gross margin of 58.3%, net margin -188.1%.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aquestive Therapeutics, Inc..
Write a review
News about Aquestive Therapeutics, Inc.
News & sentiment via Polygon.io
